Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: Primary 6-month results of the SAVE Study

Journal of Ophthalmic Inflammation and Infection

Volumn 3, Issue 1, 2013, Pages 1-15

  Nguyen, Quan Dong ^a,c   Ibrahim, Mohamed A ^a   Watters, Anthony ^a   Bittencourt, Millena ^a   Yohannan, Jithin ^a   Sepah, Yasir J ^a,c   Dunn, James P ^a   Naor, Joel ^b   Shams, Naveed ^b   Shaikh, Ovais ^a   Leder, Henry Alexander ^a   Do, Diana V ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Intravitreal; mTOR; Sirolimus; Subconjunctival; Uveitis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RAPAMYCIN;

ADULT; AGED; AHMED VALVE; ARTICLE; BACKACHE; BLURRED VISION; CATARACT; CATARACT EXTRACTION; CENTRAL MACULAR THICKNESS; CHEMOSIS; CLINICAL ARTICLE; COLONOSCOPY; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CROHN DISEASE; DETERIORATION; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EYE INFLAMMATION; EYE PAIN; EYE REDNESS; FALLING; FEMALE; FOLLOW UP; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE INFLAMMATION; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MEDICAL HISTORY; MIDDLE AGED; NON INFECTIOUS UVEITIS; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOPHAKIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RETINA MACULA EDEMA; SARCOIDOSIS; SCIATICA; SLIT LAMP; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TOOTH ABSCESS; TRABECULECTOMY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VASCULAR SURGERY; VISUAL ACUITY; WRIST FRACTURE;

EID: 84883598411     PISSN: None     EISSN: 18695760     Source Type: Journal    
DOI: 10.1186/1869-5760-3-32     Document Type: Article

References (42)

1. Whitcup SM, Chan CC, Li Q, Nussenblatt RB (1992) Expression of cell adhesion molecules in posterior uveitis. Arch Ophthalmol 110:662-666
2. Wakefield D, Easter J, Penny R (1986) Immunological abnormalities in patients with untreated retinal vasculitis. Br J Ophthalmol 70:260-265
3. Loh AR, Acharya NR (2010) Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol 150:534. e2-542. e2
4. Caspi R (2008) Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res 42:41-50
5. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889-894
6. Gupta R, Murray PI (2006) Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management. Drugs Aging 23:535-558
7. Pato E, Munoz-Fernandez S, Francisco F, Abad MA, Maese J, Ortiz A, Carmona L (2011) Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum 40:314-323
8. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Foster CS (2010) Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117:356-365
9. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492-513
10. Ikeda E, Hikita N, Eto K, Mochizuki M (1997) Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis. Jpn J Ophthalmol 41:396-402
11. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG (1995) Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 154:922-927
12. Kilmartin DJ, Forrester JV, Dick AD (1998) Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6:101-109
13. Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723-728
14. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88:1159-1162
15. Napoli KL, Taylor PJ (2001) From beach to bedside: history of the development of sirolimus. Ther Drug Monit 23:559-586
16. Sehgal SN (1998) Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31:335-340
17. Kahan BD (2001) Sirolimus: a comprehensive review. Expert Opin Pharmacother 2:1903-1917
18. Dugel PU, Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM, Naor J (2012) A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 119:124-131
19. Mudumba S, Takanaga H, Bezwada P, Wilson L, Naor J (2012) Intravitreal administration of ocular formulation of sirolimus in rabbits and humans. Invest Ophthalmol Vis Sci 53:3198
20. Nuhrenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun J, Gschwend J, Kountides M, Herter T, Baur R, Hombach V, Baeuerle PA, Zohlnhöfer D (2005) Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 19:246-248
21. Adamis AP (2002) Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 86:363-365
22. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450-1452
23. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, Naqvi S, Raza R, Patel K, Abramson D, Bruno G, Abramson SB, Amin AR (2000) Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res 49:20-26
24. Shanmuganathan VA, Casely EM, Raj D, Powell RJ, Joseph A, Amoaku WM, Dua HS (2005) The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 89:666-669
25. Phillips BN, Wroblewski KJ (2011) A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. Journal of Ophthalmic Inflammation and Infection 1:29-34
26. Wyeth (2008) Product information: RAPAMUNE(R) oral solution, oral tablets, sirolimus oral solution, oral tablets. Wyeth Pharmaceuticals Inc, Madison
27. Wyeth (2009) Product information: RAPAMUNE(R) oral solution, tablets, sirolimus oral solution, tablets. Wyeth Pharmaceuticals Inc, Madison
28. Roberts RJ, Wells AC, Unitt E, Griffiths M, Tasker AD, Allison ME, Bradley JA, Watson CJ (2007) Sirolimus-induced pneumonitis following liver transplantation. Liver Transpl 13:853-856
29. Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N (2011) Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 15:E83-E89
30. Ravaud A (2011) Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl 2):32-44
31. Soefje SA, Karnad A, Brenner AJ (2011) Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 6:125-129
32. Sofroniadou S, Goldsmith D (2011) Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Safety: an International Journal of Medical Toxicology and Drug Experience 34:97-115
33. Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, Feldman DR, Konner JA, Reidy-Lagunes D, Myskowski PL, Lacouture ME (2012) Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer 118:5078-5083
34. Braun M, Young J, Reiner CS, Poster D, Wuthrich RP, Serra AL (2012) Ovarian toxicity from sirolimus. N Engl J Med 366:1062-1064
35. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL (2008) Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 126:1191-1201
36. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL (2009) Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 116:797-801
37. Krishnadev N, Forooghian F, Cukras C, Wong W, Saligan L, Chew EY, Nussenblatt R, Ferris F, Meyerle C, 3rd (2011) Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 249:1627-1633
38. Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92:467-471
39. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509-516
40. Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21:201-230
41. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD (2001) Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119:1050-1058
42. The National Eye Institute (2000) The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). The National Eye Institute, Bethesda